European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

HEALTHCARE ALLIANCE FOR RESOURCEFUL MEDICINES OFFENSIVE AGAINST NEOPLASMS IN HEMATOLOGY – PLUS

Descrizione del progetto

DE EN ES FR IT PL

L’analisi dei dati sulle neoplasie ematologiche maligne per migliorare l’accesso a nuove terapie

Le neoplasie ematologiche maligne sono un gruppo eterogeneo di malattie caratterizzate da una diagnosi complicata e da trattamenti estremamente complessi. L’obiettivo del progetto HARMONY PLUS, finanziato dall’UE, è raccogliere, archiviare e analizzare le attuali informazioni disponibili sulle neoplasie ematologiche maligne al fine di velocizzare e sostenere il processo decisionale per l’accesso dei pazienti a nuove terapie. Il progetto si avvale delle capacità della piattaforma basata sui megadati di HARMONY per rispondere alle esigenze insoddisfatte, ampliando il campo di applicazione fino a integrare neoplasie mieloproliferative tra cui la leucosi mieloide cronica, la policitemia vera, la trombocitemia essenziale e la mielofibrosi, nonché disturbi linfoproliferativi che comprendono il linfoma di Hodgkin, la macroglobulinemia di Waldenström e tutte le neoplasie ematologiche maligne rare non prese in esame dal precedente progetto HARMONY.

Obiettivo

Haematological malignancies (HM), also known as blood cancers, are a heterogeneous and complex group of multicausal diseases that can’t be easily diagnosed nor treated. Nowadays most treatments are extremely complex, and advances in patient diagnosis and therapies slow due to the low number of patients per centre. Thus, there is a need to harmonise, store, and analyse the current HM information to speed-up and support the decision-making process for patients’ access to new therapies.

HARMONY PLUS takes advantage of the capabilities of the HARMONY Big Data platform to match these unmet needs by expanding its scope to incorporate myeloproliferative neoplasms, including chronic myeloid leukemia, polycythaemia vera, essential thrombocythaemia, and myelofibrosis; and lymphoproliferative disorders, including Hodgkin’s lymphoma, Waldenström macroglobulinemia and all the other rare HMs not covered by HARMONY Project. In parallel, HARMONY PLUS will continue to refine and define the Core Outcome Sets (COS), especially for these new HMs to ensure the use by researchers of useful common outcomes relevant to all stakeholders. As previously accomplished in HARMONY, HARMONY PLUS is committed to pursue the maximum ethical and legal requirements, particularly to ensure patient’s right to privacy.

Data-driven research within Europe will be enhanced by converting the current HARMONY platform into an Integrated Services Platform to serve as a valuable tool to support clinical trial design and use of available data as a control arm. This platform, combined with a HaemoDatabank repository with information about HMs patient biological samples across Europe, will facilitate a more efficient research and clinical trial design, and consequently will promote collaborations with recognised databases outside Europe. From the regulatory point of view, HARMONY PLUS will be a valuable technology tool during the evaluation of new treatments and drugs by also considering the patients’ needs.

Campo scientifico

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

H2020-JTI-IMI2-2019-19-single-stage

Vedi altri progetti per questo bando

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
Contribution nette de l'UE
€ 1 606 368,02
Indirizzo
PARQUE SANTA CLARA
42002 Soria
Spagna

Mostra sulla mappa
Regione
Centro (ES) Castilla y León Soria
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 2 474 594,27

Partecipanti (42)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 2 Maggio 2024

Il mio booklet

Permalink: https://cordis.europa.eu/project/id/945406/it

European Union, 2024